Pathogenic alterations in BRCA1/2 (collectively referred as BRCA) occur in up 5%–10% of prostate cancers (PCA), particularly in the metastatic castration‐resistance setting (mCRPC) [1, 2, 3, 4]. The gene discussed is BRCA1; the disease is posterior cortical atrophy.